United Kingdom: GSK v Wyeth, High Court of Justice of England and Wales, Chancery Division, Patents Court, HP-2015-000002, 12 May 2016
March 9, 2017
The UK Patents Court upheld the validity of Wyeth’s patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein used in meningitis B vaccines, rejecting GSK's allegations of lack of entitlement to two of the claimed priority dates, lack of novelty, obviousness (both conventional and so-called "AgrEvo" obviousness), insufficiency and added matter. The court also held that a number of the claims were infringed by GSK’s meningitis B vaccine, Bexsero.
A full summary of this case has been published on Kluwer IP Law.
Comments (0)
Your email address will not be published.
Become a contributor!
Interested in contributing? Submit your proposal for a blog post now and become a part of our legal community!
Contact Editorial Guidelines
